Jennifer R King

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. pmc Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients
    Jennifer R King
    University of Alabama at Birmingham, Division of Clinical Pharmacology, 1530 3rd Avenue South, Shelby 1170, Birmingham, AL 35294 0019, USA
    Antimicrob Agents Chemother 55:4290-4. 2011
  2. pmc Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, AL, USA
    Pediatr Infect Dis J 28:159-61. 2009
  3. ncbi request reprint Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
    Jennifer R King
    University of Alabama at Birmingham, Birmingham, USA
    Pediatr Infect Dis J 24:880-5. 2005
  4. pmc Novel methodology for antiretroviral quantitation in the female genital tract
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    HIV Clin Trials 10:193-9. 2009
  5. ncbi request reprint Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294, USA
    HIV Clin Trials 5:288-93. 2004
  6. ncbi request reprint Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294, USA
    Pediatr Infect Dis J 22:239-44. 2003
  7. ncbi request reprint Pharmacokinetic enhancement of protease inhibitor therapy
    Jennifer R King
    Division of Clinical Pharmacology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 43:291-310. 2004
  8. ncbi request reprint Detection of nevirapine in plasma using thin-layer chromatography
    Jeffrey G Dubuisson
    Division of Clinical Pharmacology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine, USA
    J Acquir Immune Defic Syndr 35:155-7. 2004
  9. doi request reprint Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    HIV Clin Trials 10:41-7. 2009
  10. ncbi request reprint Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers
    Jennifer R King
    PharmD, University of Alabama at Birmingham, Division of Clinical Pharmacology, 1530 3rd Avenue South, VH 116, Birmingham, AL 35294 0019, USA
    J Clin Pharmacol 47:201-8. 2007

Collaborators

Detail Information

Publications22

  1. pmc Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients
    Jennifer R King
    University of Alabama at Birmingham, Division of Clinical Pharmacology, 1530 3rd Avenue South, Shelby 1170, Birmingham, AL 35294 0019, USA
    Antimicrob Agents Chemother 55:4290-4. 2011
    ..Informal comparisons of treatment groups did not indicate any advantage to any combination with respect to tenofovir exposure. Further study of exposures achieved with antiretrovirals administered in combination is warranted...
  2. pmc Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, AL, USA
    Pediatr Infect Dis J 28:159-61. 2009
    ..Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient...
  3. ncbi request reprint Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
    Jennifer R King
    University of Alabama at Birmingham, Birmingham, USA
    Pediatr Infect Dis J 24:880-5. 2005
    ..We tested the efficacy, tolerability and pharmacokinetics of 2 combination therapies containing an NRTI, protease inhibitors +/- a nonnucleoside reverse transcription inhibitor (NNRTI)...
  4. pmc Novel methodology for antiretroviral quantitation in the female genital tract
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    HIV Clin Trials 10:193-9. 2009
    ..Challenges exist regarding antiretroviral quantitation in the female genital tract. Endocervical wicking using sterile tear flow test strips is an alternative to conventional methods due to the consistent sample volume obtained...
  5. ncbi request reprint Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294, USA
    HIV Clin Trials 5:288-93. 2004
    ..The goal of this pilot study was to describe the pharmacokinetic characteristics of protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) when administered to HIV-infected children via g-tube...
  6. ncbi request reprint Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294, USA
    Pediatr Infect Dis J 22:239-44. 2003
    ..The clinical benefits of this regimen are often accompanied by increased toxicities. We report the safety and tolerance of multiple drug therapy in HIV-infected children...
  7. ncbi request reprint Pharmacokinetic enhancement of protease inhibitor therapy
    Jennifer R King
    Division of Clinical Pharmacology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 43:291-310. 2004
    ..The following manuscript will discuss the rationale for combining protease inhibitors and will review pertinent pharmacokinetic and clinical data on these combination regimens...
  8. ncbi request reprint Detection of nevirapine in plasma using thin-layer chromatography
    Jeffrey G Dubuisson
    Division of Clinical Pharmacology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine, USA
    J Acquir Immune Defic Syndr 35:155-7. 2004
    ..This report describes a fast, inexpensive thin-layer chromatography (TLC) method to detect the presence of NVP in human plasma...
  9. doi request reprint Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    HIV Clin Trials 10:41-7. 2009
    ....
  10. ncbi request reprint Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers
    Jennifer R King
    PharmD, University of Alabama at Birmingham, Division of Clinical Pharmacology, 1530 3rd Avenue South, VH 116, Birmingham, AL 35294 0019, USA
    J Clin Pharmacol 47:201-8. 2007
    ..Although SQV plasma concentrations were higher when coadministered with RTV, a combination of SQV/ATV administered BID may be a viable alternative in HIV-infected, PI-naive subjects intolerant to RTV...
  11. pmc Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 56:5938-45. 2012
    ....
  12. ncbi request reprint Tipranavir: a novel nonpeptidic protease inhibitor of HIV
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 45:665-82. 2006
    ..Therefore, this novel PI in combination with ritonavir represents an important new choice in the treatment of multiple-PI-experienced patients...
  13. ncbi request reprint Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, Ala, USA
    Antivir Ther 7:267-70. 2002
    ....
  14. ncbi request reprint Persistence of nevirapine in breast milk after discontinuation of treatment
    Chantelle Bennetto-Hood
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    Clin Infect Dis 45:391-4. 2007
    ..Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts...
  15. ncbi request reprint Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy
    Jennifer R King
    University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama, USA
    AIDS 19:1059-63. 2005
    ..To describe the in vivo protein-binding characteristics of indinavir (IDV) in the presence of ritonavir (RTV) relative to total IDV plasma concentrations...
  16. ncbi request reprint Effects of concentration and temperature on the stability of nevirapine in whole blood and serum
    Chantelle J Bennetto
    The University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, 1530 3rd Ave South, VH 116, Birmingham, AL 35294 0019, USA
    Clin Chem 50:209-11. 2004
  17. ncbi request reprint Antiretroviral pharmacokinetics in the paediatric population: a review
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0019, USA
    Clin Pharmacokinet 41:1115-33. 2002
    ..If prevention of treatment failure continues to be the goal of antiretroviral therapy, the pharmacokinetics of antiretrovirals in children need to be assessed early in the drug development process...
  18. ncbi request reprint Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294 0019, USA
    Clin Infect Dis 36:373-7. 2003
    ....
  19. pmc Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults
    Gautam Baheti
    Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198 6000, USA
    AIDS 27:221-5. 2013
    ..Our objectives were to describe TFV-DP pharmacokinetics in children and adolescents and investigate the effect of age on TFV and TFV-DP concentrations...
  20. ncbi request reprint Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography
    Michele L Turner
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, VH 116, 35294 0019, Birmingham, AL, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 784:331-41. 2003
    ..Recovery from plasma was consistently high (>80%). This novel HPLC methodology allows us to simultaneously determine plasma concentrations of nine antiretrovirals, including lopinavir, in HIV-infected patients on a single HPLC system...
  21. ncbi request reprint The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil
    Lori K Mattison
    Division of Clinical Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 6th Avenue South, Birmingham, AL 35294, USA
    Clin Cancer Res 12:549-55. 2006
    ..In the present study, we characterize the relationships among UraBT-associated breath (13)CO(2) metabolite formation, plasma [2-(13)C]dihydrouracil formation, [2-(13)C]uracil clearance, and DPD activity...
  22. ncbi request reprint Pharmacokinetic optimization of antiretroviral therapy in pregnancy
    Kajal Buckoreelall
    Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
    Clin Pharmacokinet 51:639-59. 2012
    ..It is necessary to consider the pharmacological characteristics of each antiretroviral when optimizing combination therapy during pregnancy to treat maternal HIV infection and prevent perinatal HIV transmission...